retatrutide phase 2 trial type 2 diabetes results 2024 Lilly's triple agonist achieves 16.8% weight loss in 3 Perceived benefits of treatment for

Curr Diabetes Rev 14(3):273279 Mousavi A et al (2025) Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Building your personal GLP-1 before and after plan Every successful GLP-1 transformation begins with a plan

The most important intervention to support growth is optimizing nutritional support during GLP-1 treatment, he says

Many people with obesity already carry internalized shame and guilt, and while GLP-1s may provide a solution to obesity, they dont come without stigmas of their own